.[J] Chinese Pharmaceutical Journal, 2011,V46(23): 1855-1856
��
[1]
FDA. Label approved on 11/15/2010 for HALAVEN, NDA no. 201532[EB/OL]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf.[2] Twelves C, Cortes J, Vahdat L T, et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer[J]. Clin Breast Cancer, 2010,10(2):160-163.[3] JENNIFER A S, LESLIE W, OLGA AZARENKO, et al. Eribulin Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability[J]. Biochem�� 2010, 49(6): 1331�C1337.[4] JAVIER C, ALBERTO J M, STEFAN G. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer[J]. Cancer Treat Rev, 2011, 22��10����1-12.